Prostate Cell News Volume 2.08 | Mar 4 2011

University of Surrey’s Diagnostic Urine Test: A Real Breakthrough
Scientists have made a major breakthrough in the early diagnosis of prostate cancer. [Press release from the University of Surrey discussing online prepublication in Clinical Cancer Research]

Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men with Bone Metastases from Advanced Prostate Cancer
Amgen announced the publication of results from a Phase III head-to-head trial that compared XGEVA™ (denosumab) to Zometa® (zoledronic acid) in preventing bone complications called skeletal-related events in 1,901 men with prostate cancer and bone metastases. [Press release from Amgen Inc. discussing online prepublication in The Lancet]

LABORATORY RESEARCH

Fyn Is Downstream of the HGF/MET Signaling Axis and Affects Cellular Shape and Tropism in PC3 Cells
This study defines the biological impact of Fyn inhibition in cancer using a PC3 prostate cancer model. [Clin Cancer Res]

Human Prostate Cancer Harbors the Stem Cell Properties of Bone Marrow Mesenchymal Stem Cells
Scientists examined human prostate cancer cell lines and clinical prostate cancer specimens for additional bone marrow mesenchymal stem cell properties. [Clin Cancer Res]

The Cancer/Testis Antigen Prostate-Associated Gene 4 (PAGE4) Is a Highly Intrinsically Disordered Protein
PAGE4 is the first example of a cancer/testis antigen that is an intrinsically disordered protein with an anti-apoptotic function. [J Biol Chem]

The Impact of Amyloid Precursor Protein Signaling and Histone Deacetylase Inhibition on Neprilysin Expression in Human Prostate Cells
The expression of neprilysin (NEP) in neuronal cells is regulated by intramembrane proteolysis of the amyloid precursor protein through its intracellular domain facilitating histone acetylation of the NEP promoter and gene transcription. The present study examined whether similar mechanisms operate in prostate cell lines. [Int J Cancer]

The Significance of Her2 on Androgen Receptor Protein Stability in the Transition of Androgen Requirement in Prostate Cancer Cells
Androgen ablation therapy is the most common strategy to suppress prostate cancer progression; however, tumor cells eventually escape androgen dependence and progress to an androgen-independent phase. To address this transition mystery in prostate cancer, investigators established an androgen-independent prostate cancer cell line (LNCaPdcc), by long-term screening of LNCaP cells in androgen-deprived conditions, to investigate changes of molecular mechanisms before and after androgen withdrawal. [Am J Physiol Endocrinol Metab]

Docosahexaenoic Acid Selectively Induces Human Prostate Cancer Cell Sensitivity to Oxidative Stress Through Modulation of NF-κB
Scientists investigated the effects of docosahexaenoic acid (DHA-22:6n-3) in modulating the effects of oxidative DNA damage in LNCaP and PacMetUT1 human prostate adenocarcinoma cells and in a normal human prostate cell line, PrEC. [Prostate]

hZIP1 Zinc Transporter Down-Regulation in Prostate Cancer Involves the Overexpression of Ras Responsive Element Binding Protein-1 (RREB-1)
The aim of this study was to determine if RREB-1 transcription is involved in the down-regulation of ZIP1 gene expression; and to determine the expression of RREB-1 in benign and cancerous prostate in situ. [Prostate]

SWAP70, Actin-Binding Protein, Function as an Oncogene Targeting Tumor-Suppressive miR-145 in Prostate Cancer
The aim of this study is to determine a novel oncogenic gene targeted by miR-145 by focusing on actin-binding proteins in prostate cancer. [Prostate]

Therapeutic Targeting of SPINK1-Positive Prostate Cancer
Scientists examined the potential of serine peptidase inhibitor, Kazal type 1 (SPINK1) as an extracellular therapeutic target in prostate cancer. [Sci Transl Med]

CLINICAL RESEARCH

Denosumab Versus Zoledronic Acid for Treatment of Bone Metastases in Men with Castration-Resistant Prostate Cancer: A Randomized, Double-Blind Study
Researchers compared denosumab, with zoledronic acid for prevention of skeletal-related events in men with bone metastases from castration-resistant prostate cancer. [The Lancet]

Impact of Comorbidity on Survival Among Men with Localized Prostate Cancer
The purpose of the study is to provide patients and clinicians more accurate estimates of comorbidity-specific survival stratified by patient age, tumor stage, and tumor grade. [J Clin Oncol]

Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer
Investigators assessed the diagnostic potential of EN2 protein, a homeodomain-containing transcription factor expressed in prostate cancer cell (PC) lines and secreted into the urine by PC in men. [Clin Cancer Res]

The Association Between Radiographic Response and Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Chemotherapy
In men with metastatic castration-resistant prostate cancer, the association of measurable tumor responses with overall survival is unknown. The authors retrospectively evaluated the TAX327 Phase III trial to study this relation. [Cancer]

CD8+ T Cells Specific for the Androgen Receptor Are Common in Patients with Prostate Cancer and Are Able to Lyse Prostate Tumor Cells
Scientists evaluate the androgen receptor ligand-binding domain as an immunological target, seeking to identify HLA-A2-restricted epitopes recognized by T cells in prostate cancer patients. [Cancer Immunol Immunother]

Immunotope and Immunovaccine Announce U.S. Patent for Therapeutic Cancer Vaccine Antigens
Immunotope Inc. and Immunovaccine Inc. announced that the U.S. Patent and Trademark Office has issued an official Notice of Allowance for a new U.S. Patent specific to the DPX-0907 therapeutic cancer vaccine. [Immunovaccine Inc. Press Release]

Ipsen and bioMérieux Enter into a Broad Partnership in Personalized Medicine
Ipsen and bioMérieux announced that they have entered into a partnership to create a global collaboration in theranostics, with a focus on hormone-dependent cancers. [Ipsen Press Release]

GTx and Ipsen Terminate Their Toremifene Collaboration
GTx, Inc. announced that the company and Ipsen have mutually agreed to terminate their collaboration for the development and commercialization of toremifene. [GTx, Inc. Press Release]

The Smilow Comprehensive Prostate Cancer Center Installs Eigen ei-Nav|Artemis™
The Smilow Comprehensive Prostate Cancer Center at New York University Langone Medical Center is the first medical facility in the Northeast to install ei-Nav|Artemis™, an innovative image guidance and navigation system for prostate biopsy that is manufactured by Eigen. [PR Newswire]

Davos Life Science Receives Research Excellence Award from Frost & Sullivan
Davos Life Science announced that it has been awarded the 2010 Asia Pacific Frost & Sullivan Excellence in Research Award in the Natural Vitamin E Market. [Davos Life Science Press Release]

Dendreon Reports Fourth Quarter and 2010 Year End Financial Results
Dendreon Corporation reported results for the year and quarter ended December 31, 2010. [Dendreon Corporation Press Release]

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 20th Annual American Association for Cancer Research Aspen Workshop: Molecular Biology in Clinical Oncology
July 16-22, 2011
Snowmass, United States

Visit our events page to see a complete list of events in the prostate cell community.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.